Novel class therapies developer Vedanta Biosciences has entered into a translational collaboration with the NYU Langone Medical Centre in New York, US, to develop effective microbiome-derived immunotherapies for cancer patients being treated with checkpoint inhibitors.

As part of the deal, Vedanta will work closely with Dr Jeffrey S. Weber-led team of oncologists from Langone Laura and Isaac Perlmutter Cancer Centre.

The collaboration will focus on clinical studies that would be directed towards the identification of new microbiome immunotherapies for cancer.

Vedanta chief scientific officer Dr Bruce Roberts said: “Dr Weber is a pioneer in translational research, particularly in immunotherapy and the development of checkpoint inhibitors.

"Dr Weber is a pioneer in translational research, particularly in immunotherapy and the development of checkpoint inhibitors."

“We look forward to working with Dr Weber to expand Vedanta’s portfolio of immune activating microbial cocktails for use in standalone immunotherapy and in combination with checkpoint inhibitors.”

The researchers will also try to discover different mechanisms, by which the gut microbiome can influence the efficacy of checkpoint inhibitors in cancer patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Dr Weber said: “Checkpoint inhibitors are a major advance in cancer therapy, but many patients do not respond to therapy, and some patients who do respond will eventually relapse.

“Recent data suggests an important role for the microbiome in the anti-tumour activity of immunotherapy, and our other studies of the microbiome will offer interesting new clinical insights into how and why these treatments work.

“Further understanding of the role of the microbiome in immunotherapeutic responses against cancer may also lead to new and improved therapies.”

A recent study conducted by Vedanta co-founder Dr Kenya Honda at Keio University has revealed human-dwelling bacterial strains can activate immune cells in the gut that can be used for immunotherapies.

Other researches demonstrate that gut bacteria can potentially modulate the therapeutic responses to checkpoint blockades, along with other classes of cancer therapeutics.